Source: Annual Congress 2013 - Lunchtime Session "Tiotropium soft mist inhaler and mortality in COPD: results of the TIOSPIR clinical trial"
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
O. Yusuf (Islamabad, Pakistan). The way forward: how to link real-life situations and clinical trial results. Annual Congress 2013 - Lunchtime Session "Tiotropium soft mist inhaler and mortality in COPD: results of the TIOSPIR clinical trial"

Member's Comments

No comment yet.

Related content which might interest you: Translating trials to clinical practice: results ²more real than real life itself²¹ Source: Annual Congress 2007 - Smoking cessation Year: 2007 Telemonitoring in clinical practice: a way forward? Source: Annual Congress 2013 –Primary Care Programme "Asthma management in clinical practice" Year: 2013 From clinical trials to real-world data: New dimensions of patient benefits Source: International Congress 2015 – IgE-mediated asthma: New revelations and future insights Year: 2015 Pirfenidone: an update on clinical trial data and insights from everyday practice Source: Eur Respir Rev 2014; 23: 111-117 Year: 2014 A new model for clinical trials to address the COVID-19 emergency Source: Breathe, 16 (2) 200220; 10.1183/20734735.0220-2020 Year: 2020 Do the current endpoints in IPF clinical trials allow good regulatory decisions to be made? Source: International Congress 2014 – Ceremony for the ERS Rare Pulmonary Disease Research Award 2014 followed by the symposium "Challenges in endpoints for rare lung diseases" Year: 2014 New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response Source: Eur Respir Rev 2014; 23: 367-378 Year: 2014 How to accelerate bringing new drugs to patients: role of clinical trials networks Source: International Congress 2019 – Rare lung diseases Year: 2019 Randomised controlled trials and real-life studies: two answers for one question Source: Eur Respir Rev, 27 (149) 180080; 10.1183/16000617.0080-2018 Year: 2018 Negative clinical trials in sarcoidosis: failed therapies or flawed study design? Source: Eur Respir J 2014; 44: 1123-1126 Year: 2014 Evaluation of factors to consider prior to adjustment of biologic quality control ranges using data from a large multi-centre clinical trial Source: Annual Congress 2009 - Quality control in lung function and new developments Year: 2009 The future of translational lung cancer research: from classical randomised controlled trials to innovative platform trials Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer Year: 2018 Real world effects of COPD medications: a cohort study with validation against results from randomised controlled trials Source: Eur Respir J, 57 (3) 2001586; 10.1183/13993003.01586-2020 Year: 2021 Real life vs ideal life: What can we learn from clinical trials and observational studies of COPD Source: International Congress 2019 – Putting COPD patient needs first: Time for optimizing treatment and device selection Year: 2019 Is our approach to basic research right? Pitfalls and successes: what is the way forward? Source: ERS Research Seminar 2016 Year: 2016 SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network Source: Eur Respir J, 56 (3) 2002114; 10.1183/13993003.02114-2020 Year: 2020